drugset
drugset / Trial / NCT06362759

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

NCT06362759 ↗

Phase 2 Completed 143 enrolled Tourmaline Bio, Inc., a Novartis Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.

Timeline

Start
2024-05-15
Primary completion
2025-03-06
Completion
2025-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PACIBEKITUG Monoclonal antibody 15 mg Subcutaneous
Subject PACIBEKITUG Monoclonal antibody 25 mg Subcutaneous
Subject PACIBEKITUG Monoclonal antibody 50 mg Subcutaneous

Indications

chronic kidney disease